This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site



Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyOff-contract claimsAlliance Healthcare

Example content



AboutAboutTherapy Area OverviewRisk Factors of Ulcerative ColitisDiagnosingDiagnosingSigns and SymptomsComorbidities & PathophysiologyTreatmentTreatment guidelinesPfizer Treatment OptionsDisease NavigatorDisease NavigatorDisease NavigatorTreatmentTreatment guidelinesPfizer Treatment Options

Xeljanz®(tofacitinib citrate) Prescribing information and Inflectra®(infliximab) Prescribing information. Adverse event reporting can be found at the bottom of the page.

An Overview of Ulcerative Colitis

Ulcerative Colitis (UC) is the most common form of Inflammatory Bowel Disease (IBD).1

IBD is a group of disorders that cause chronic inflammation in the GI tract. Inflammation leads to damage of GI organs and impairs their ability to function properly. The most common forms of IBD are UC and Crohn's Disease (CD)

The exact cause of IBD is unkown; however, it is thought to involve interactions between genes, the immune system, and environmental factors.

What is Ulcerative Colitis?H3 (Mobile)

In UC, ongoing inflammation is limited to the large intestine (colon) and rectum and affects only the innermost lining of these organs2. Inflammation leads to the formation of ulcers (sores) that can bleed and result in bloody stools, the hallmark symptom of UC2,5

UC DemographicsH3 (Mobile)

Click on the drop downs below to learn about key demographic characteristics of Ulcerative Colitis

Worldwide prevalence of UC
  • Considerable variation in the epidemiology of UC around the world.
  • Associated with industrialised and Westernised environments.
  • The highest incidence and prevalence of UC are found in North America & Europe.
  • The incidence and prevalence of UC are increasing overtime. 4
Prevalence by age
  • While UC can occur at any age, it commonly affects younger individuals.2
  • UC has a bimodal pattern of incidence.5
    • The majority of individuals are diagnosed betwen ages 15 and 30 years.
    • There is a second, smaller peak of individuals diagnosed between ages 50 and 70 years
Prevalence by gender
  • IBD affects men and women equally, although some studies show that UC is more common in men that women.2

1. National Institute of Diabetes and Digestive and Kidney Diseases. [Document on the Internet]. 2016 Jan 1 [cited 2016 Dec 13]. Available from:
Crohn’s and Colitis Foundation of America. The facts about inflammatory bowel diseases. 2014. [Document on the Internet]. 2014 Jan 1 [cited 2016 Dec 14]. Available from:
3. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011; 365:1713-1725.
4. Molodecky NA, Soon IS, Rabi DM. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142(1):46-54.
5. Ordás I. Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012; 380:1606-1619.

Learning Academy
Inflammation Disease Navigator

Click below to view the Immuno-navigator tool. An interactive tool to help you manage discussions with your patients . 

Visit the Navigator Tool
Click Through to Pfizer Brand SitesPatient Support Materials (pdf)
PP-IFA-GBR-0633. May 2023

Adverse events should be reported. Reporting forms and information can be found at or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2023 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-UNP-GBR-4885. May 2023


For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
You are now leaving PfizerPro
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021